08 jun: Damark/vismand: Regeringen skal finde nye penge
10 jun: Overskud i APM´s containerforretning
08-06-2012 23:55:00

J&J to Record $600 Million Charge in 2Q

Relateret indhold

Johnson & Johnson (JNJ) said it plans to record a special charge of roughly $600 million in its second quarter to increase its accrual for potential legal settlements, as it has faced a series of lawsuits over accusations of bribery and improper drug-marketing practices.

The company said the settlement payments stem for a series of outstanding civil cases that involve its drugs Risperdal, Invega and Natrecor, as well as nursing-home pharmacy operator Omnicare Inc. (OCR).

The health-care products company has faced lawsuits related to alleged off-label promotion of its antipsychotic treatment Risperdal, which was once J&J's top-selling drug before generic copycats hit the market, as well as legal challenges over off-label promotion of another schizophrenia treatment, Invega, and the heart-failure drug Natrecor.

Furthermore, the federal government is suing J&J, accusing it of paying kickbacks to induce Omnicare to encourage use of Risperdal and other J&J drugs.

In addition, J&J has dealt with state lawsuits regarding its promotion of Risperdal, including an Arkansas case in which the company in April was ordered to pay $1.2 billion after a jury found that J&J's past marketing of the drug violated the state's consumer-protection laws. J&J previously was ordered to pay $327 million in a South Carolina case and $258 million in Louisiana. The company is appealing all three cases.

In January, J&J agreed to settle a Texas case for $158 million.

Meanwhile, the company agreed to pay an $85 million fine in a criminal case regarding off-label marketing of Natrecor. Parallel civil litigation still hasn't been settled.

The company in April said its first-quarter earnings rose on a foreign-exchange-related gain tied to an acquisition and lower expenses.

Shares closed Friday at $62.98 and were unchanged after hours. The stock is down 4% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

(END) Dow Jones Newswires

June 08, 2012 17:55 ET (21:55 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Aktier/tendens: Vestas kan komme i fokus i lysegrønt marked

29-03-2017 08:44:42
En større amerikansk satsning på olie og kul kan sætte Vestas i fokus fra morgenstunden, i et marked der ser ud til at åbne i plus.Præsident Donald Trump underskrev tirsdag et dekret om at tilbagerulle centrale dele af sin forgængers, Barack Obamas, klimalovgivning. Og Trump vil blandt andet fjerne et af Obamas tiltag, Clean Power Plan, fordi det ifølge dem er en hindring for olieboring og kulmine..

Første 20.000 teu-containerskib er sat i søen

28-03-2017 16:18:00
Det første containerskib, der officielt har brudt grænsen på 20.000 tyvefodscontainere (teu) i kapacitet, er nu i søen.Det blev det japanske rederi Mitsui OSK Lines, også kaldet MOL, der tog titlen med skibet MOL Triumph.Skibet har en officiel kapacitet på 20.170 teu og er det første i en serie af seks skibe på samme størrelse, som sydkoreanske Samsung Heavy Industries bygger for MOL.Containerskib..

Mærsk/Snabe: Stolt af og ydmyg over for opgaven

28-03-2017 12:38:10
Jim Hagemann Snabe, ny bestyrelsesformand for A.P. Møller-Mærsk, træder til opgaven med stolthed og ydmyghed. Det siger han selv fra talerstolen på selskabets generalforsamling tirsdag, hvor han overtager formandsrollen fra Michael Pram Rasmussen.- Jeg er glad for den tillid bestyrelsen og hovedaktionæren har vist ved at udtrykke opbakning til mig som ny bestyrelsesformand. Jeg er stolt over men o..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Bilforhandler glæder sig til ny model: Det bliver en storsællert
2
Økonom: Frygtens indeks i bund - mulig bølgegang forude
3
Første 20.000 teu-containerskib er sat i søen
4
Genmab/fmd: Egen salgsstyrke er et realistisk mål
5
Genmab/CEO: Priserne på kræftmidler vil komme under pres

Relaterede aktiekurser

Johnson & Johnson 125,66 0,0% Aktiekurs uændret

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Copyright Euroinvestor A/S 2017  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
29. marts 2017 09:24:40
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20170324.2 - EUROWEB3 - 2017-03-29 09:24:40 - 2017-03-29 09:24:40 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x